Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
46&
- Development stage
- Preclinical
- Lead developer
- CAMBIOTICS
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
46& is a precision-formulated oral probiotic supplement developed by Cambiotics for the detoxification and reduction of per- and polyfluoroalkyl substances (PFAS) body burden. The product consists of two natural, non-GMO bacterial strains, 46-XY1 (from the Streptococcus family) and 46-SL1 (from the Bacteroides family), which are designed to bioaccumulate long-chain PFAS molecules—specifically PFOS, PFNA, PFDA, and PFOA—within the gastrointestinal tract. By sequestering these "forever chemicals," the therapy enhances their fecal excretion, thereby preventing systemic absorption and reducing the overall body burden. Developed in collaboration with the MRC Toxicology Unit at the University of Cambridge, 46& is currently in preclinical development with plans for clinical trials in healthy individuals with elevated PFAS levels.
- Brand names
- 46&
- Other names
- 46-XY1 + 46-SL1Cambiotics PFAS probioticCambiotics bacterial therapy
Beyond the preview
Go deeper on 46&.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 46&.